NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026

for a period or periods up to a total of 24 months. Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

NHS Branded Medicines Tranche B - Lot 1 - London & South of England - CM/PHR/25/5731 Period of Framework Agreement: 1 September 2026 to 31 August 2028 with an option or option(s) to extend (at the Authority’s discretion)